Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s12250-020-00270-x http://scihub22266oqcxt.onion/10.1007/s12250-020-00270-x 32705575!7376096!32705575     free     free     free Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Virol+Sin 2020 ; 35 (6): 752-757 Nephropedia Template TP {{tp|p=32705575|t=2020. Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity |pdf=|usr=}}{{32705575}} gab.com Text Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity JO: Virol Sin http://www.kidney.de/pget.php?&tw=1&pmid=32705575 #FOAvip The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity. Twit Text FOAVip Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity ????Virol Sin http://www.kidney.de/pget.php?&tw=1&pmid=32705575 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32705575 #FOAvip English Wikipedia <ref>{{Cite pmid|32705575}}</ref> Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different Severity #MMPMID32705575 Kong WH; Zhao R; Zhou JB; Wang F; Kong DG; Sun JB; Ruan QF; Liu MQ Virol Sin 2020[Dec]; 35 (6): 752-757 PMID32705575show ga The immense patient number caused by coronavirus disease 2019 (COVID-19) global pandemic brings the urge for more knowledge about its immunological features, including the profile of basic immune parameters. In this study, eighty-eight reported COVID-19 patients in Wuhan were recruited from January to February, 2020, including 32 severe/critical cases and 56 mild/moderate cases. Their mean age was 56.43 years (range 17-83) and gender ratio (male/female) was 43:45. We tested SARS-CoV-2 RNA with commercial kits, investigated the level of serologic IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) using magnetic particle chemiluminescence immunoassays, and compared the results of serologic tests and nucleic acid test (NAT). Among 88 patients, 95.45% were confirmed as positive by the combination of NAT and antibody test, which was significantly higher (P < 0.001) than by single nucleic acid test (73.86%) or serologic test (65.91%). Then the correlation between temporal profile and the level of antibody response was analyzed. It showed that seroconversion started on day 5 after disease onset and IgG level was rose earlier than IgM. Comparison between patients with different disease severity suggested early seroconversion and high antibody titer were linked with less severe clinical symptoms. These results supported the combination of serologic testing and NAT in routine COVID-19 diagnosis and provided evidence on the temporal profile of antibody response in patients with different disease severity. |Adolescent[MESH] |Adult[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Antibodies, Viral/immunology[MESH] |Antibody Formation[MESH] |COVID-19 Nucleic Acid Testing/methods[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/blood/epidemiology/*immunology/*virology[MESH] |China/epidemiology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin G/blood/immunology[MESH] |Immunoglobulin M/blood/immunology[MESH] |Luminescent Measurements/methods[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Real-Time Polymerase Chain Reaction/methods[MESH] |SARS-CoV-2/genetics/*immunology[MESH]Serologic Response to SARS-CoV-2 in COVID-19 Patients with Different S(epmc).pdf DeepDyve Pubget Overpricing